BIOVERATIV INC (NASDAQ:BIVV) – Equities researchers at William Blair increased their FY2017 earnings per share estimates for shares of BIOVERATIV INC in a research note issued to investors on Monday. William Blair analyst R. Prasad now forecasts that the biotechnology company will post earnings per share of $2.51 for the year, up from their prior estimate of $2.50. William Blair also issued estimates for BIOVERATIV INC’s Q4 2017 earnings at $0.54 EPS, FY2018 earnings at $2.68 EPS, FY2019 earnings at $2.70 EPS and FY2020 earnings at $2.62 EPS.
Several other research firms also recently weighed in on BIVV. Zacks Investment Research raised BIOVERATIV INC from a “hold” rating to a “strong-buy” rating and set a $73.00 price objective on the stock in a report on Tuesday, July 25th. Cowen and Company reissued a “buy” rating and set a $80.00 price objective on shares of BIOVERATIV INC in a report on Friday, August 4th. Piper Jaffray Companies reissued an “overweight” rating and set a $71.00 price objective on shares of BIOVERATIV INC in a report on Monday, October 23rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $70.00 target price (up from $67.00) on shares of BIOVERATIV INC in a research report on Wednesday, August 9th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $47.00 target price (up from $45.00) on shares of BIOVERATIV INC in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $61.73.
BIOVERATIV INC (NASDAQ:BIVV) last released its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. BIOVERATIV INC had a return on equity of 69.03% and a net margin of 40.44%. The company’s quarterly revenue was up 27.2% compared to the same quarter last year.
In other BIOVERATIV INC news, Director Louis J. Paglia acquired 2,000 shares of the stock in a transaction dated Monday, August 7th. The stock was purchased at an average cost of $59.70 per share, with a total value of $119,400.00. Following the transaction, the director now owns 5,056 shares in the company, valued at approximately $301,843.20. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Brian S. Posner acquired 1,000 shares of the stock in a transaction dated Wednesday, August 9th. The stock was acquired at an average cost of $59.19 per share, with a total value of $59,190.00. Following the completion of the transaction, the director now owns 6,693 shares in the company, valued at approximately $396,158.67. The disclosure for this purchase can be found here.
Hedge funds have recently bought and sold shares of the company. Whittier Trust Co. of Nevada Inc. bought a new position in shares of BIOVERATIV INC in the 3rd quarter worth about $293,000. Quotient Investors LLC bought a new position in shares of BIOVERATIV INC in the 3rd quarter worth about $420,000. Rockefeller Financial Services Inc. bought a new position in shares of BIOVERATIV INC in the 3rd quarter worth about $1,480,000. Tirschwell & Loewy Inc. bought a new position in shares of BIOVERATIV INC in the 3rd quarter worth about $2,068,000. Finally, Raymond James Trust N.A. bought a new position in shares of BIOVERATIV INC in the 3rd quarter worth about $297,000. 92.93% of the stock is owned by hedge funds and other institutional investors.
BIOVERATIV INC Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
What are top analysts saying about BIOVERATIV INC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BIOVERATIV INC and related companies.